QUECTEL-WIRELESS
10.11.2022 10:01:40 CET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, announces that its industrial-grade 5G NR module RG500L-EU has gained GCF certification for operating on global 5G NR networks. The GCF certification means that the RG500L-EU module can help customers to efficiently deploy their 5G high-speed IoT devices worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109006142/en/
Quectel, a global IoT solutions provider, announces GCF certification for it's industrial-grade 5G NR module RG500L-EU (Photo: Business Wire)
Based upon the MediaTek T750 platform, the RG500L-EU integrates a 5G NR FR1 modem and a quadcore Arm Cortex-A55 processor. By leveraging the powerful CPU performance of the T750 chipset, customer devices can improve their device processing performance as well as enable significant cost optimization.
“The global certification by the GCF confirms our commitment to provide our customers with best-in-class IoT solutions, no matter where they are in the world,” said Dominikus Hierl, Senior Vice President Sales EMEA. “Quectel continues to drive IoT innovation, providing the very best in 5G modules and delivering the innovation our customers have come to expect in order to develop their 5G IoT applications.”
The module supports dual carrier aggregation (2CC CA) at 200MHz frequency band. This capability to combine available 5G spectrum assets can greatly improve signal coverage and transmission rates. Additionally, the RG500L-EU module can achieve a peak downlink rate of 4.67Gbps and a peak uplink rate of 1.25Gbps, bringing smooth and super-fast 5G speed experience to end users.
The RG500L-EU supports EasyMesh™ and WPA3 R3 encryption protocol, enabling IoT devices with more stable, cost-efficient and secure wireless connections. The module also offers flexible Wi-Fi configuration combinations, including single 5G 2x2 + 2.4G 2x2 dual-band, single 5G 4x4 + single 2.4G 4x4 dual-band, as well as single 5G 4x4 (5G high frequency band) + single 5G 4x4 (5G low frequency band) + single 2.4G 4x4 tri-band.
Featuring a compact design and low power consumption, the RG500L-EU can help customers to reduce time-consuming procedures including fixed network and equipment installation. Its rich peripheral interfaces including SGMII, PCIe and PCM give customers maximum flexibility in their IoT solution designs. In combination with Quectel’s unique QuecOpen platform, the RG500L-EU also improves customer terminal development efficiency and accelerates their time-to-market.
The RG500L-EU adopts an 8-antenna solution with four 2.7GHz antennas and four n77/n78 dedicated antennas to provide terminals with stronger and more stable signals as well as higher peak download rates. The module can additionally provide high gain antenna covering n78 band to help with signal reception.
In addition to the GCF certification, Quectel's 5G module RG500L-EU has also passed CE approval for the EU market as well as RCM approval for the Australian region. In the above areas, Quectel’s RG500L-EU module has already been chosen by customers to develop a variety of terminals including mobile hotspots, customer premise equipment (CPE), outdoor unit (ODU) and other 5G converged gateways and industrial gateways, which have been deployed in areas like industrial monitoring, remote collaboration, video conferencing, telemedicine, online education and many other fields.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth® modules, antennas and IoT connectivity. With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109006142/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Even Realities Brings Classic Tortoiseshell Design to Smart Glasses with New Even G2 Brown 226.10.2026 15:00:00 CET | Press release
The new brown colorway pairs traditional eyewear craftsmanship with display-first technology, alongside Even G2 Clip (Polarized) and Even G2 Chain Even Realities, the company behind camera-free, display-first smart glasses, today introduced Brown 2, a new tortoiseshell-inspired colorway for Even G2, alongside two accessories: Even G2 Clip (Polarized) and the Even G2 Chain. Designed to bring the warmth and character of traditional tortoiseshell eyewear to smart glasses, Brown 2 features a newly developed material that carries its layered pattern throughout the frame rather than applying it as a surface finish. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026502782/en/ Even G2 Chain. Photo Credit: Even Realities Each frame is individually shaped, pressed, tumbled, and polished for 20 hours, creating subtle variations that make every pair unique. Brown 2 is also the lightest Even G2 design to date, while retaining the came
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 202626.10.2026 14:45:00 CET | Press release
INCB161734 (KRAS G12D inhibitor) and INCA338901 (TGFβR2×PD-1 bispecific antibody) data reinforce ongoing and planned registrational trials, including DAWN-303 in pancreatic ductal adenocarcinoma (PDAC) and NEXERA-303 in colorectal cancer (CRC), respectivelyNew data evaluating INCB161734 in CRC highlight its clinical activity across KRAS G12D-mutated tumor types and support initiation of a Phase 3 study in second-line CRC planned for 2027INCB161734 and INCA33890 demonstrated manageable safety profiles in combination with standard-of-care (SoC) chemotherapiesNew collaborations with Bristol Myers Squibb and Synnovation in PDAC to evaluate INCB161734 in combination with navlimetostat, an MTA-cooperative PRMT5 inhibitor, and SNV1521, a PARP1 inhibitor, respectivelyThese results and additional updates will be presented at an analyst and investor event on Monday, October 26, 2026, from 7:30 – 9:00 p.m. CET (2:30 – 4:00 p.m. EDT) Incyte (Nasdaq:INCY) announced new results from its advancing on
Bending Spoons Completes the Acquisition of Miro26.10.2026 14:00:00 CET | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) has completed the previously announced acquisition of Miro, the visual collaboration platform used by more than 250,000 organizations to brainstorm, plan, and build together. “Miro has built a strong business around a product that makes complex collaborative work feel simple,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Miro’s versatility has made it useful across a broad range of industries and workflows, while creating a robust foundation for further expansion. We believe there’s significant potential to build on these strengths. We look forward to drawing on Bending Spoons’ technologies and expertise to make Miro even more useful to customers and support its continued growth.” “Teams depend on Miro for innovating, alignment, coordination, and decisioning, and that need is only growing,“ said Andrey Khusid, CEO and co-founder of Miro. “In Bending Spoons, Miro has an owner who invests for the long term and cares deeply about product quali
Dubai Culture Opens Registration for ISEA2026 Dubai26.10.2026 13:09:00 CET | Press release
Dubai Culture and Arts Authority (Dubai Culture) has opened registration for the 31st International Symposium on Electronic/Emerging Art (ISEA2026 Dubai), taking place from 6 to 15 November 2026 under the theme ‘ELYAH: Constellating Place, Data and Identity’. The symposium will be the largest edition to date, bringing together artists, researchers, and innovators from around the world to explore the intersection of art, science, and technology and exchange perspectives on the future of contemporary creative practice. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026652826/en/ Dubai Culture Opens Registration for ISEA2026 Dubai (Graphic: AETOSWire) The event supports Dubai Culture’s efforts to advance the digital arts ecosystem, deliver on its Digital Arts Roadmap objectives, and empower local talent. It also reinforces Dubai’s position as a global cultural reference, a leader in innovation, a driver of the creative econo
Agendia Unveils Clinical Validation of AI-Driven Digital Pathology Approach26.10.2026 13:00:00 CET | Press release
The investigational AI-driven digital assay demonstrated high concordance with MammaPrint results in the prospective RASTER cohort of 372 early-stage breast cancer patients with a median follow-up of 10.3 years Agendia, Inc., a leader in precision oncology for breast cancer, recently presented research introducing its investigational artificial intelligence (AI)-driven digital pathology approach for the MammaPrint®70-gene recurrence signature at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The podium presentation, delivered by co-founder and Chief Research Officer, Laura van ’t Veer, Ph.D., detailed the development and clinical validation of a deep learning pipeline that can infer MammaPrint (MP) risk categories directly from hematoxylin and eosin (H&E)-stained, whole-slide images (WSIs). The company also presented two additional posters highlighting data from the prospective, real-world FLEX Study (NCT03053193). “AI has been part of Agendia’s scientific fo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom